Researchers trained machine learning (ML) models to analyze RNA molecular signatures in patients’ blood.
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy – Pharmaceutical Technology
DMD is a rare, progressive genetic disorder characterised by the degeneration and weakness of muscles. Credit: Raja GamerXTC via Shutterstock. RegenxBio has revealed plans to